Semaglutide (CAS registry number 910463-68-2) is a 31-amino acid glucagon-like peptide-1 (GLP-1) receptor agonist in which the lysine residue homologous to position 26 of native GLP-1(7–37) is modified with a γ-glutamic acid–two-unit 2-(2-aminoethoxy)ethoxy acetic acid–octadecanedioic acid linker. The free-base peptide has the molecular formula C187H291N45O59 and a molecular weight of 4113.58 g/mol; the exact counterion, whether acetate, trifluoroacetate, or sodium, must be stated on the lot certificate because it changes salt weight and free-peptide molar concentration. The product described here is an R&D-grade active pharmaceutical ingredient supplied as a lyophilized powder for formulation development across tablets, capsules, granules, injections, and oral or injectable feasibility studies. It is not a finished dosage form, not a sterile injectable product, and not approved for human use. The supplier model code is lot-specific rather than compendial; it must be mapped to the certificate of analysis and safety data sheet. Release documentation should be maintained under a quality system aligned with ICH Q7 and ISO 9001:2015; electronic analytical records should meet 21 CFR Part 11 and EU GMP Annex 11 where used in a GMP-analogous setting.

Representative release controls for the lyophilized peptide are summarized in the following table. Exact acceptance criteria are lot-specific and should be confirmed against the certificate of analysis before use in sensitive assays.

Peptide concentration for in vitro and in vivo work is calculated on the free-peptide equivalent, not on total salt weight. If semaglutide sodium or another salt form is supplied, the certificate should include counterion content by ion chromatography and the free-base assay. The user should not assume that peptide purity equals free peptide content; the two values diverge when water, residual solvent, and counterion contribute to total powder mass.

What Distinguishes R&D-Grade Semaglutide from Reference-Listed Drug Substance and Compounded Peptide Supply?

R&D-grade semaglutide is released as an unformulated active ingredient. A reference listed drug substance includes the same peptide sequence and linker but is supported by a full registration file and is not generally sold as a laboratory reagent. The approved oral finished product contains the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC); the R&D API does not contain SNAC, buffer salts, antioxidants, or preservatives unless specifically listed on the certificate. This absence is technically relevant because oral permeation studies that omit SNAC may yield poor apparent permeability and should not be interpreted as an intrinsic failure of the peptide. Injectable reference products are formulated to target pH, tonicity, and subvisible-particle control; the R&D powder must be diluted into a suitable vehicle before injection. Compounded peptide supply, in contrast, may lack full impurity profiling, counterion verification, or residual solvent testing. A sponsor evaluating multiple sources should compare the same orthogonal methods: RP-HPLC purity, mass spectrometry, water content, residual solvents, and counterion content. A certificate of analysis that reports only peptide purity and water content is insufficient for route-specific development.

Compared with liraglutide, semaglutide carries a C18 diacid attached through a two-unit OEG spacer rather than a C16 palmitoyl monoacid attached through a single γ-glutamic acid spacer. Compared with exenatide, semaglutide is not an exendin-4 sequence but a long-acting GLP-1 analogue with fatty acylation. Compared with tirzepatide, semaglutide is a GLP-1 receptor agonist only, while tirzepatide is a dual GIP/GLP-1 receptor agonist. These structural differences affect route-specific R&D work: oral formulation screening for semaglutide must address its acylation, molecular weight, and absorption-enhancer dependence, whereas injectable screening must control fatty acid–induced aggregation and surface adsorption.

Solid-Form Screening, Salt Selection, and Counterion Control

The solid-state form of the as-received lot should be established by X-ray powder diffraction and differential scanning calorimetry. Because many lyophilized peptide powders are amorphous and hygroscopic, the user should not assume a particular crystallinity without measurement. If a crystalline or salt form is required for tableting or for a solid dispersion program, screening should be conducted with pharmaceutically acceptable counterions such as acetate or hydrochloride, but no public semaglutide solid-form monograph establishes a default form. When switching from free base to semaglutide sodium, the laboratory must recalculate all molar doses using the free-peptide assay; the difference in counterion mass can be 1–5% depending on salt stoichiometry. Do not mix salt forms within a stability study without a formal bridging protocol. If the user intends to prepare an oral tablet or capsule, the acyl chain hydrophobicity and molecular weight are formulation-critical, and the approved oral product uses SNAC as an absorption enhancer; however, published data for this specific research configuration is limited.

For immediate-release tablet or capsule screening, the peptide should be interrogated for particle size by laser diffraction according to ISO 13320:2020, for bulk and tapped density by USP ⟨616⟩, and for powder flow by USP ⟨1174⟩. Low-humidity handling is used because hydrate formation or surface water can change weigh accuracy and blend uniformity. If the as-received particle size is unsuitable for direct compression or capsule filling, dry mesh sieving or particle engineering steps such as dry milling are evaluated; these operations must be justified experimentally because published data on semaglutide powder behavior in dry-milling circuits are limited.

When Formulation Development Moves from Dry Blending to High-Shear Granulation

Dry blending of semaglutide with filler and disintegrant should begin with a low-shear tumble blender or cube blender operating at 10–25 rpm; blend uniformity is evaluated by HPLC with sampling at 10–15 locations. If high-shear granulation is used, the process window should be established on an instrumented mixer with torque and power-draw monitoring. Typical screening conditions for peptide powders range from impeller speeds of 200–500 rpm and chopper speeds of 1000–3000 rpm, but these are not semaglutide-specific and must not be transferred without experimental verification. The binder solution should be selected after forced degradation studies because peptide degradation rates are pH- and temperature-dependent. For tablet compression, a compaction simulator or instrumented rotary press is recommended; ejection force and sticking should be recorded because acylated peptides can exhibit surface adhesion or punch filming. If the formulation contains SNAC, the blend should be tested for content uniformity because SNAC loadings in approved oral semaglutide are high relative to peptide load, and the resulting binary mixture can be sensitive to segregation.

Before injection, a low-concentration vehicle is typically prepared by dissolving semaglutide at 1–10 mg/mL in a 10–50 mM phosphate or acetate buffer adjusted to pH 3.5–7.4, with tonicity adjusted using sodium chloride or mannitol. The solution is filtered through a 0.22 µm PVDF or PES membrane. Osmolality is measured according to USP ⟨785⟩, and subvisible particles are evaluated by light obscuration or membrane microscopy according to USP ⟨787⟩. Dynamic light scattering per ISO 22412:2017 is used to detect soluble aggregates; if the polydispersity index exceeds 0.2 or multimodal distributions appear, buffer optimization is required. Terminal heat sterilization by autoclaving is not recommended for peptide solutions because thermal degradation may occur; aseptic filtration is the standard route for laboratory preparation of injectable peptides.

Are Endotoxin and Subvisible Particle Control More Critical for Injectable Feasibility?

Endotoxin and subvisible particle control are more critical for parenteral feasibility because a lot acceptable for oral gavage or in vitro receptor binding may be unsuitable for injection if endotoxin and subvisible particle release data are absent. A typical parenteral R&D acceptance criterion is ≤ 0.5 EU/mg by USP ⟨85⟩. Subvisible particle testing according to USP ⟨787⟩ is applied to the constituted solution after filtration; results should meet the limits for 10 µm and 25 µm particles. For injectable feasibility, the vehicle components must be compendial or equivalent, and the final solution should be stored at 2–8 °C and used within the protocol-defined window. Do not assume that an oral-grade lot can be converted to injectable grade by aseptic filtration alone; filtration removes microorganisms but does not remove endotoxin or chemical aggregates.

The following compliance matrix summarizes the minimum release and analytical interface for route-specific development.

Thermal and Humidity Stress Inside the Unopened Primary Container Requires Controlled Storage

Long-term storage of the lyophilized peptide should be at −20 °C ±5 °C in a desiccated primary container, protected from light. Before opening, the sealed container should be equilibrated to ambient temperature inside a desiccator to avoid moisture condensation on the powder; if the handling suite exceeds 60% relative humidity, the user should pre-dry the desiccator and minimize open exposure to a validated interval, commonly less than 30 min but lot-specific. Repeated freeze-thaw cycling of the dry powder is discouraged because static charge and hydration can alter weigh accuracy. Once reconstituted, stability is formulation-dependent and must be generated in-house; do not store reconstituted peptide in phosphate-buffered saline at room temperature beyond the protocol-defined window. For shipping, the lot should be packed with validated cold-chain packaging and a temperature logger; any excursion above 0 °C for more than 24 h without stability data should trigger a quality review because published data on the dry peptide’s thermal stability outside the primary container are limited.